Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Stevanato Group S.p.A. (NYSE:STVN) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company.

Several equities research analysts recently weighed in on STVN shares. CJS Securities started coverage on shares of Stevanato Group in a research note on Tuesday, September 19th. They set an “outperform” rating and a $36.00 target price on the stock. Wells Fargo & Company boosted their price target on shares of Stevanato Group from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 31st. KeyCorp boosted their price target on shares of Stevanato Group from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Wednesday, August 30th. Morgan Stanley lowered their price target on shares of Stevanato Group from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, November 1st. Finally, Stephens started coverage on shares of Stevanato Group in a report on Monday, September 25th. They set an “overweight” rating and a $33.00 price target for the company.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. MML Investors Services LLC boosted its holdings in shares of Stevanato Group by 5.2% in the 2nd quarter. MML Investors Services LLC now owns 9,077 shares of the company’s stock valued at $294,000 after buying an additional 449 shares in the last quarter. Fifth Third Bancorp grew its position in Stevanato Group by 47.2% during the 2nd quarter. Fifth Third Bancorp now owns 1,454 shares of the company’s stock worth $47,000 after purchasing an additional 466 shares during the last quarter. Natixis Advisors L.P. grew its position in Stevanato Group by 2.6% during the 3rd quarter. Natixis Advisors L.P. now owns 23,409 shares of the company’s stock worth $696,000 after purchasing an additional 590 shares during the last quarter. UBS Group AG grew its position in Stevanato Group by 79.9% during the 1st quarter. UBS Group AG now owns 1,799 shares of the company’s stock worth $36,000 after purchasing an additional 799 shares during the last quarter. Finally, US Bancorp DE raised its stake in Stevanato Group by 170.7% during the 1st quarter. US Bancorp DE now owns 1,340 shares of the company’s stock valued at $35,000 after acquiring an additional 845 shares during the last quarter. Institutional investors and hedge funds own 10.90% of the company’s stock.

Stevanato Group Price Performance

Stevanato Group stock opened at €27.92 ($30.68) on Tuesday. The company’s 50 day simple moving average is €29.62 and its 200-day simple moving average is €30.33. The company has a market capitalization of $8.25 billion, a price-to-earnings ratio of 47.32, a price-to-earnings-growth ratio of 4.08 and a beta of 0.87. Stevanato Group has a 1 year low of €14.02 ($15.41) and a 1 year high of €36.30 ($39.89). The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.91 and a current ratio of 1.41.

Stevanato Group (NYSE:STVN) last announced its earnings results on Tuesday, October 31st. The company reported €0.16 ($0.18) earnings per share for the quarter, hitting the consensus estimate of €0.16 ($0.18). Stevanato Group had a net margin of 14.05% and a return on equity of 14.87%. The firm had revenue of €295.39 million for the quarter, compared to the consensus estimate of €305.22 million. As a group, equities research analysts expect that Stevanato Group will post 0.61 earnings per share for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for biopharma and healthcare. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.